Secondary Logo

Institutional members access full text with Ovid®

ACR–ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer

Savir-Baruch, Bital, MD; Banks, Kevin P., MD; McConathy, Jonathan E., MD, PhD; Molchanova-Cook, Olga P., MD, PhD; Parent, Ephraim E., MD, PhD; Takalkar, Amol, MD, MS, MBA, FACNM; Tulchinsky, Mark, MD; Yu, Jian Q., MD, FRCPC, FACNM; Subramaniam, Rathan M., MD, PhD, MPH; Schuster, David M., MD, FACR

doi: 10.1097/RLU.0000000000002310
Original Articles

The American College of Radiology (ACR) and American College of Nuclear Medicine (ACNM) collaborated to develop a clinical practice document for the performance of fluciclovine positron-emission tomography (PET) / computed tomography (CT) in the evaluation of patients with suspected prostate cancer recurrence based on the elevation of prostate-specific antigen (PSA) level (biochemical recurrence) after prior therapy. Prostate cancer is the third leading cause of cancer death in the United States. Up to 50% of patients diagnosed with prostate cancer will develop biochemical failure after initial therapy. The differentiation of local from extraprostatic recurrence plays a critical role in patient management. The use of functional imaging targeting features of cancer metabolism has proven highly useful in this regard. Amino acid transport is upregulated in prostate cancer. Fluciclovine (anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic acid, FACBC, Axumin™) is an artificial amino acid PET tracer which demonstrates utility in the diagnosis of recurrent prostate cancer with significant added value to conventional imaging.

From the UT Southwestern Medical Center Dallas, TX.

Received for publication July 20, 2018; revision accepted July 27, 2018.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Bital Savir-Baruch, MD, Loyola Univ Med Ctr, Radiology, 2160 S 1st Ave. Maywood, IL. E-mail:

Practice parameters and technical standards are published annually with an effective date of October 1 in the year in which amended, revised or approved by the ACR Council. For practice parameters and technical standards published before 1999, the effective date was January 1 following the year in which the practice parameter or technical standard was amended, revised, or approved by the ACR Council.

Development Chronology for This Practice Parameter: Adopted 2018 (Resolution 32).

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.